No products in the cart.
Pre-Made Dazodalibep Biosimilar, Fusion Protein targeting CD40LG fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting CD154/CD40L/HIGM1/IGM/IMD3/T-BAM/TNFSF5/TRAP/gp39/hCD40L for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-INN-798
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Dazodalibep Biosimilar, Fusion Protein targeting CD40LG fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting CD154/CD40L/HIGM1/IGM/IMD3/T-BAM/TNFSF5/TRAP/gp39/hCD40L is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Dazodalibep is a novel, non-antibody fusion protein that blocks CD40 ligand (CD40L) activity that has been shown to reduce B cell activation and autoantibody production, potentially halting inflammation and autoimmunity.
| Products Name (INN Index) | Pre-Made Dazodalibep Biosimilar, Fusion Protein targeting CD40LG fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting CD154/CD40L/HIGM1/IGM/IMD3/T-BAM/TNFSF5/ |
|---|---|
| INN Name | dazodalibep |
| Target | CD40LG |
| Format | Fusion Protein |
| Derivation | synthetic construct |
| Species Reactivity | Human |
| CH1 Isotype | Fusion – Alternative to antigen receptors (domain scaffold: TNC-F3, tenascin domain F3) 2 TNC- F3 domains |
| VD LC | Fusion – Alternative to antigen receptors (domain scaffold: TNC-F3, tenascin domain F3) 2 TNC- F3 domains |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Viela?Bio,?Inc. (Gaithersburg MD USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | Alternative to antigen receptors, domain scaffold TNC F3, tenascin domain F3 |
| Previous Name | NA |
| Gm Offical Target Name | CD40LG |
| Package |
Previous slide
Next slide
